Prelude Therapeutics Company Insiders

Prelude Therapeutics Management Team Effectiveness

The company has return on total asset (ROA) of (0.4505) % which means that it has lost $0.4505 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.8144) %, meaning that it created substantial loss on money invested by shareholders. Prelude Therapeutics' management efficiency ratios could be used to measure how well Prelude Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of July 20, 2025, Return On Tangible Assets is expected to decline to -0.76. In addition to that, Return On Capital Employed is expected to decline to -0.98. At present, Prelude Therapeutics' Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Total Current Assets is expected to grow to about 177.2 M, whereas Non Currrent Assets Other are forecasted to decline to about 3.2 M. As of July 20, 2025, Common Stock Shares Outstanding is expected to decline to about 48.5 M. In addition to that, Net Loss is expected to decline to about (109.1 M)

Prelude Therapeutics Workforce Comparison

Prelude Therapeutics Insider Trading

Prelude Therapeutics Notable Stakeholders

The success or failure of an entity such as Prelude Therapeutics often depends on how effective the management is. Prelude Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Prelude management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Prelude management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.

Please note, the presentation of Prelude Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Prelude Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Prelude Therapeutics' management manipulating its earnings.

When running Prelude Therapeutics' price analysis, check to measure Prelude Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Prelude Therapeutics is operating at the current time. Most of Prelude Therapeutics' value examination focuses on studying past and present price action to predict the probability of Prelude Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Prelude Therapeutics' price. Additionally, you may evaluate how the addition of Prelude Therapeutics to your portfolios can decrease your overall portfolio volatility.